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Introduction
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Insulinotropic sulphonylureas such as tolbutamide and Although sulphonylureas are known to exert acute stimu-39 latory effects upon insulin secretion [3] , several studies have 40 suggested that chronic treatment with these drugs leads to 41 a decline in their insulinotropic activity [8] [9] [10] [11] , an observa-42 tion which has been attributed to a direct desensitisation of 43 the pancreatic beta-cell to the actions of these drugs [12, 13] . 44 This desensitisation effect has been suggested to be due to 45 a decline in beta-cell K ATP channel activity [14, 15] . Such 46 observations may be of clinical significance given the ten-47 dency of sulphonylurea therapy for type 2 diabetes to pro-48 gressively fail [16] .
49
In vitro studies of the chronic effects of sulphonylureas 50 on insulin secretion have been limited by the decline in 51 insulin production by pancreatic islets during extended pe-52 riods in tissue culture [17] . This difficulty has been largely 53 surmounted by the development of insulin-secreting cell 54 lines which are stable over time in tissue culture [18, 19] . 55 One such cell line is BRIN-BD11, developed by electro-56 fusion of New England Deaconess Hospital (NEDH) rat 57 pancreatic beta-cells with RINm5F cells [20] , a cell line 58 originally derived from an NEDH rat insulinoma [21] . The 59 BRIN-BD11 cell line has been shown to possess key com- 
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ponents of the insulin secretory mechanism [18,19,22- 
Statistical analysis 145
Results are presented as mean±standard error of the mean 146 (S.E.M.) for a given number of observations (n). Groups 147 of data were compared by two-way ANOVA in conjunc-148 tion with Bonferroni's modified t-statistics. Differences were 149 considered significant if P < 0.05. Both tolbutamide (1.9-fold increase; P < 0.001) and 154 glibenclamide (2.9-fold increase; P < 0.001) stimulated in-155 sulin release from BRIN-BD11 cells cultured under stan-156 dard conditions (Fig. 1 ). Culture with 25-100 M tolbu-157 YPHRS 1300 1-6 Fig. 1 . BRIN-BD11 cells were cultured for 72 or 144 h in either standard RPMI-1640 tissue culture medium, or RPMI supplemented with 5, 25 or 100 M tolbutamide, media being changed every 24 h. Following 144 h culture with tolbutamide, culture media were replaced by standard RPMI medium for a further 72 or 144 h, media being changed every 24 h. Following 40 min preincubation, effects of 200 M tolbutamide or glibenclamide were tested during a 20 min acute exposure period in the presence of 1.1 mM glucose. Values are mean ± S.E.M. (n = 6). * P < 0.05, * * P < 0.01, * * * P < 0.001 when compared with control (1.1 mM glucose). P < 0.05, P < 0.001 when compared with culture in absence of tolbutamide.
tamide for 72-144 h significantly reduced acute secretory 158 responsiveness to tolbutamide and glibenclamide (Fig. 1A   159 and B).
160
The stimulatory effect of tolbutamide on insulin release 161 was abolished following 144 h exposure to 25 or 100 M 162 tolbutamide, whilst glibenclamide retained an insulinotropic 163 action (1.3-and 1.5-fold increase; each P < 0.05) (Fig. 1B) .
164
When these secretory data are expressed as a percentage of 165 cellular insulin content (as reported in (1.3-and 1.5-fold increase; P < 0.01 and P < 0.001).
169
Exposure to standard culture conditions for 72-144 h 170 (recovery time) following 144 h exposure to tolbutamide 171 resulted in decreased tolbutamide-stimulated insulin se-172 cretion (Fig. 1C and D) . Tolbutamide was without acute 173 insulinotropic effect in cells which had been previously 174 exposed to 25 or 100 M of the drug, whilst glibenclamide 175 retained an insulinotropic action (1.4-and 1.5-fold increase, 176 respectively; both P < 0.001) (Fig. 1C and D (Fig. 1D) . (n = 6). * P < 0.05, * * P < 0.01, * * * P < 0.001 when compared with control (1.1 mM glucose). P < 0.05, P < 0.01, P < 0.001 when compared with culture in absence of glibenclamide.
YPHRS 1300 1-6 (n = 6). * P < 0.05, * * * P < 0.001 when compared with culture in absence of sulphonylurea. P < 0.05, P < 0.01, P < 0.001 when compared with 0 h recovery. sulin release ( Fig. 2A and B) . However, secretory respon- Fig. 2A and B) . This abolition is also noted when 193 secretory output data is expressed as a percentage of cellular 194 insulin content (as reported in Table 1 ).
Effects of chronic glibenclamide exposure on
195
Culture for 72-144 h exposure to standard culture con- (Table 1 ). This effect was reversed by 72-144 h re-219 covery under standard culture conditions. Glibenclamide at 220 5, 25 or 100 M similarly decreased cellular insulin content 221 during 72-144 h cultures. The effect was more pronounced 222 than equimolar tolbutamide, but reversible by 72-144 h 223 subsequent culture following all but the highest (100 M) 224 glibenclamide concentration (Table 1) . 
227
RNA samples from BRIN-BD11 cells under each culture 228 condition tested were analysed by RT-PCR for K ATP channel 229 subunits Kir6.2 and SUR1. These studies revealed the pres-230 ence of both Kir6.2 and SUR1 transcripts in BRIN-BD11 231 cells (Fig. 3) . Kir6.2 and SUR1 mRNA remained detectable 232 following 144 h culture in the presence of 5, 25 or 100 M 233 tolbutamide or glibenclamide (Fig. 3A and C) . in Kir6.2 or SUR1 transcription levels were noted following 237 these conditions (Fig. 3B and D) . 
285
Unlike nutrient secretagogues, sulphonylureas do not 286 stimulate insulin biosynthesis, but rather only stimulate 287 release of preformed insulin, leading to beta-cell degran-288 ulation [1, 29, 30] . Accordingly, chronic 72 h exposure of 289 BRIN-BD11 cells to tolbutamide (25 and 100 M) and 290 glibenclamide (5, 25 and 100 M) decreased cellular insulin 291 content. The more marked depletion by glibenclamide was 292 expected, given that it is a more potent insulin secretagogue 293 than tolbutamide [3] . The effects of 100 M sulphonylurea 294 persisted but insulin content of cells cultured at 25 M 295 tolbutamide or 5 or 25 M glibenclamide were normalised 296 after recovery for 144 h. Interestingly, restoration of cellu-297 lar insulin content corresponded with unexpected increases 298 in sulphonylurea-stimulated insulin release, implying that 299 these events may be linked. However, a clear dissociation 300 between the chronic effects of sulphonylureas on insulin 301 secretion and cellular insulin content existed under other 302 experimental conditions. This is particularly interesting in 303 light of the fact that sulphonylurea receptors have been 304 reported to be localised upon insulin secretory granules 305 [31], but further studies must be undertaken to determine if 306 this is due to an effect of sulphonylureas on the exocytotic 307 mechanism.
308
As sulphonylureas regulate insulin secretion by inter-309 acting with K ATP channels [4, 5] , it was clearly valuable 310 to examine the effects of chronic drug exposure on the 311 YPHRS 1300 1-6 transcription of components of these channels. RT 
